Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 1.00 |
| ▸ | RXRB | P28702 | 10/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 6/20 | 1.00 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 1.00 |
| ▸ | RXRG | P48443 | 7/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | RARB | P10826 | 5/20 | 0.59 |
| ▸ | RARG | P13631 | 5/20 | 0.59 |
| ▸ | RARA | P10276 | 3/20 | 0.57 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218800 | 1.00 | RXRA (1.00) | RXRARXRBCYP26A1CYP26B1RXRG | |
| Ammonia Solution, Strong SCHEMBL8706695 | 0.99 | RXRA (0.97) | RXRARXRBCYP26A1CYP26B1RXRG | |
| Ammonia Solution, Strong SCHEMBL8706692 | 0.99 | RXRA (0.97) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL7463646 | 0.95 | RXRA (1.00) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL30011660 | 0.95 | RXRA (1.00) | RXRARXRBCYP26A1CYP26B1RXRG | |
| Ammonia Solution, Strong SCHEMBL8706569 | 0.94 | RXRA (0.97) | RXRARXRBCYP26A1CYP26B1RXRG | |
| Ammonia Solution, Strong SCHEMBL8706564 | 0.94 | RXRA (0.97) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL17914374 | 0.90 | CYP26A1 (1.00) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL7451775 | 0.90 | RXRA (0.81) | RXRARXRBCYP26A1CYP26B1RXRG | |
| SCHEMBL8608030 | 0.86 | RXRA (0.75) | RXRARXRBCYP26A1CYP26B1RXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2026-03-10 | — | — | US | claimed |
| US-20260009005-A1 | GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS | THE CLEVELAND CLINIC FOUNDATION | 2026-01-08 | — | — | US | claimed |
| US-12435315-B2 | Generating dorsal foregut, and anterior domain, endoderm cells | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-10-07 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| CN-119768510-A | Methods and compositions for producing hematopoietic endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119654404-A | Methods and compositions for producing oligodendrocyte progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119585416-A | Methods and compositions for generating endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2025024484-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER | DUKE UNIVERSITY (US) | 2025-01-30 | — | — | WO | claimed |
| CN-114096557-B | Production of dorsal foregut and anterior endoderm cells | 克利夫兰诊所基金会 | 2024-12-13 | — | — | CN | claimed |
| US-20220220447-A1 | GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS | THE CLEVELAND CLINIC FOUNDATION | 2022-07-14 | — | — | US | claimed |
| CN-114096557-A | Generation of germ layer cells in the dorsal foregut and anterior structural domains | 克利夫兰诊所基金会 | 2022-02-25 | — | — | CN | claimed |
| US-7045315-B2 | Methods for modulating expression of exogenous genes in mammalian systems | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2006-05-16 | — | — | US | claimed |
| US-20020187972-A1 | Methods for modulating expression of exogenous genes in mammalian systems | THE SALK INSTITUTE OF BIOLOGICAL STUDIES | 2002-12-12 | — | — | US | claimed |
| US-6333318-B1 | USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2001-12-25 | — | — | US | claimed |
| EP-1076569-A1 | FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2001-02-21 | — | — | EP | claimed |
| WO-1999058155-A1 | FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-11-18 | — | — | WO | claimed |
| US-5767148-A | 4-((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHYL) CARBONYLBENZOIC ACID ETHYLENE ACETAL AND 4-((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHYL) CARBOXYLAMIDOBENZOIC ACID HAVING RETINOID ACTIVITYP; LEUKEMIA | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | claimed |
| EP-0694301-B1 | Synergistic combination containing at least a RXR specific ligand and a RAR alpha specific ligand | CIRD GALDERMA (FR) | 1996-11-13 | — | — | EP | claimed |
| WO-1996023080-A1 | GENE SEQUENCE INDUCED IN SKIN BY RETINOIDS | ALLERGAN (US) | 1996-08-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187972-A1 | Methods for modulating expression of exogenous genes in mammalian systems | NR2E3, GFRA2, GFRA3 | RXRA 691/4885RXRB 796/4885CYP26A1 694/4885 |
| US-20260009005-A1 | GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLS | BMP4, BMPR2, DACH1 | RXRA 71/4885RXRB 60/4885CYP26A1 2856/4885 |
| US-12571046-B2 | Methods of detecting and treating multiple system atrophy | SYNJ1, MYT1, SYNJ2 | RXRA 18/4885RXRB 10/4885CYP26A1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.